Marshall Strother

I hereby submit my twitter petition for all journal article pdfs to automatically include the supplementary materials at the end. Extra clicks + pain of organizing extra PDFs >>> a few extra wasted KB of hard drive space @JUrology

JUST IN: VOLGA Phase III is (+)=>Neoadjuvant Durva+EV and adjuvant Durva alone showed EFS & OS benefit. The shorter period of EV is a very attractive option! @DanaFarber_GU @OncoAlert @OncBrothers @AstraZeneca @tompowles1 @AUC3_Official

🔥 POISE-3 Urology published in European Urology 🚨 In the largest randomized placebo-controlled #urology analysis of #TranexamicAcid (TXA), #TXA reduced major #bleeding risk by 37% (from 9.5% to 6.1%) with no clear increase in #thrombosis More at sciencedirect.com/science/articl… #EBM

For those of us who still do some laparotomies. Small vs Large Bites for Abdominal Midline Incisions jamanetwork.com/journals/jamas…

6️⃣ So, what is new today? ✅Central path review of RP specimens from ProtecT 🧐Which early-stage cancers metastasize? 🚨Spoiler alert🚨 Cribriform!

Just in: The phase 3 Talapro-3 trial met its primary endpoint!!! fiercepharma.com/pharma/pfizer-… @OncoAlert @AUC3_Official

9️⃣ years later, the story of dual immune checkpoint blockade in metastatic RCC is still being written. The final "very" long-term follow-up of CheckMate-214 confirms what many hoped in 2018: durable survival, deep responses, and a subset of patients who may experience long-term disease control with nivolumab + ipilimumab. A short 🧵 on what 9+ years of follow-up teach us about immunotherapy in kidney cancer since Bernard Escudier @myESMO 2018 plenary presentation sciencedirect.com/science/articl…

R3 LITESPARK-022: Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab for Clear Cell Renal Cell Carcinoma #GU26 showed significantly delayed DFS HR 0.72 (95% CI, 0.59–0.87) active across all subgroups. Immature OS (30 mnth OS 93% CDs 96%). ⬆️ Anaemia fatigue and transaminitis but only 4% discontinuation rate for belzutifan. The shape of the DFS curve and early OS trending the right way looks like initial analysis of KN564 and we know where that ended, making pem/bel attractive. @OncoAlert @DrChoueiri

🆕adjuvant combo for #RCC : LITESPARK-022 #GU26 DFS: HR: 0.72‼️ OS: inmature data..... but comparator arm was THE most effective active treatment available. @DrChoueiri @tompowles1 @BourlonMaite @ASCO

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

In EMBRACE RCT, we demonstrated utility of an ERAS protocol for ambulatory TURBT for quality of recovery for patients @mike_rezaee @MaxKates @SHPatelMD1 @mihiggins22 @KMRodriguez19 @brucetrock Yuezhou Jing @nirmishsingla @Sad_Sep @brady_urology auajournals.org/doi/10.1097/JU…

@ElliotServaisMD "A surgeon uses the literature like a drunk uses a lamppost: more for support thank illumination." -Rick Billingham

📢 New publication in European Urology We are pleased to highlight a new study published in European Urology, titled "Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial". 👏 Congratulations to Hiroshi Kitamura et al. on this excellent contribution, together with all co-authors. 🔗 Read the full article here: 👉 lnkd.in/ePEvrQDY #EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

doi.org/10.1016/j.euru… Final THOR-2 analysis: Oral erdafitinib significantly improved RFS vs intravesical chemotherapy and produced durable CRs in FGFR-altered HR & IR #NMIBC—bringing precision oncology into NMIBC care. @JimCatto @nikhilvasdevuro @PignotG @BladderCancerUS @IBCG_BladderCA @EUplatinum @Uroweb @UroOnc #FGFR #PrecisionOncology #UroOnc #ClinicalTrials

During @ASCO #GU26, 2 positive RPIII will be presented: LS011 and LS022. Both adding HIF2 inhibitor (@NobelPrize 2019 story with @kaelin_lab et al) to standard of care. Both Trials positive. Saturday Feb 28 will be the day RCC achieves another milestone. @OncoAlert @kidneycan @KidneyCancer @motzermd @NCCN

Results from the phase II TOMBOLA published in @Annals_Oncology ctDNA+ patients treated early with atezolizumab (60% CR) and ctDNA– patients safely spared adjuvant therapy (97% 1-year RFS). @OncoAlert @LDyrskjot @urotoday annalsofoncology.org/article/S0923-…

@CanesDavid @jasonryanmd @EvidenceOpen @uretericbud .@uretericbud helps run AdrenalMass.org for just these kinds of questions! Short answer is it's low yield and different guidelines say different things but we ultimately recommended just doing it adrenalmass.org/practice-updat…

@jasonryanmd @EvidenceOpen Not sure that's the right litmus test. It's an "in the weeds" enough question that not every specialist might know. There is a right answer, and I suspect it's "no" a workup isn't required. paging @uretericbud

OpenEvidence isn't infallible. I asked on one computer - do adrenal myelolipomas require functional workup? Answer: no Same question on another computer - Answer: yes @EvidenceOpen

Do we need to routinely image the pelvis in surveillance of Stage I testicular cancer? Multi-institutional retrospective study showing 1.3% pts with no prior cryptorchidism or inguinal/scrotal surgery had pelvis only recurrence. @HamedA3112 @UMNUrology @uroegg @RHamiltonUrol @TarikBenidir @AlonLazarovich sciencedirect.com/science/articl…

Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women—a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU) - Clinical Microbiology and Infection clinicalmicrobiologyandinfection.org/article/S1198-…

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU clinical trials in 2025! 1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%. @tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO nejm.org/doi/full/10.10…

Fascinatingly counterintuitive If observation is indeed true, many potential explanations (P.S. article in same issue shows surgeon mortality is higher than non-surgeon physicians) Association Between Surgeon Stress and Major Surgical Complications jamanetwork.com/journals/jamas…